Skip to content

Dose for Deep Neuromuscular Blockade Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade

Find Out the Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04688268
Enrollment
90
Registered
2020-12-29
Start date
2021-01-10
Completion date
2021-07-30
Last updated
2020-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Surgery

Keywords

laparoscopic surgery, deep neuromuscular blockade

Brief summary

Find out the deciding factor(total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) of neuromuscular blocker dose for deep neuromuscular blockade.

Detailed description

Before the surgery, total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index were measured by height and weight and skeletal muscle mass and body fat were measured by Bioelectrical impedance analysis (InbodyH20N). Find the highest correlation between the 8 factors (total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) and the amount of rocuronium administered to deep neuromuscular blockade.

Interventions

Train of Four=0/4, Post tetanic count 1-2

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo laparoscopic surgery for at least 2 hours under general anesthesia

Exclusion criteria

* kidney disease (GFR\<60) * allergy to study drugs * decline participation * side effect of propofol and remifentanil * when anesthesia does not maintain the level of alertness (BIS) below 60 even when the anesthetic dose is increased, or when hemodynamic instability such as bradycardia and hypotension appears

Design outcomes

Primary

MeasureTime frameDescription
the highest correlation coefficientpreoperative 1 days to postoperative 1 daysthe relationship of rocuronium for deep neuromuscular blockade and 8 factors (corrected body weight, ideal body weight, lean body weight, fat-free mass, body mass index, skeletal muscle mass, body fat)

Secondary

MeasureTime frameDescription
onset time of rocuroniumpreoperative 1 days to postoperative 1 daystime from injection of rocuronium 0.6 mg/kg(TBW) to TOF ratio is less than 0.05
Time to deep neuromuscular blockadepreoperative 1 days to postoperative 1 daystime from injection of rocuronium 0.6 mg/kg(TBW) to PTC 1
Recovery timepreoperative 1 days to postoperative 1 daystime from sugammadex injection to TOF ratio \> 0.9

Contacts

Primary ContactJiwon Han, Dr
hanjiwon@snubh.org82-10-3447-1988
Backup ContactAh-young Oh, Dr
oay1@snubh.org82-31-787-7506

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026